Lamotrigine

Overview

Lamotrigine is an anticonvulsant medication used primarily to treat epilepsy and bipolar disorder. It works by stabilizing electrical activity in the brain to reduce seizures and mood swings.

API suppliers (31)

Suppliers of Lamotrigine evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.

• COHANCE LIFESCIENCES LTDIndia2 active DMF GMP on record
• Iol Chemicals And Pharmaceuticals LimitedIndia2 active DMF GMP on record
• TAPI NL BVNetherlands1 active DMF
• JUBILANT BIOSYS LTDIndia1 active DMF
• MEDICHEM SASpain1 active DMF GMP on record
• Zydus Lifesciences LimitedIndia1 active DMF GMP on record
• EMNAR PHARMA PRIVATE LTDIndia1 active DMF
• MATRIX PHARMACORP PRIVATE LTDIndia1 active DMF
• Unichem Laboratories Ltd.India1 active DMF GMP on record
• UNIMARK REMEDIES LTDIndia1 active DMF
• Zhejiang Huahai Pharmaceutical Co., Ltd.China1 active DMF GMP on record
• CTX LIFE SCIENCES PVT LTDIndia1 active DMF
• SYN-TECH CHEM AND PHARM CO LTDTaiwan1 active DMF
• SMS Pharmaceuticals limitedIndia1 active DMF GMP on record
• Cipla USA, Inc.USA1 active DMF
• DR REDDYS LABORATORIES LTD1 active DMF GMP on record
• ZAKLADY FARMACEUTYCZNE POLPHARMA SA1 active DMF
• Alembic Pharmaceuticals LimitedIndia1 active DMF GMP on record
• Taro Pharmaceutical Industries Ltd.Israel1 active DMF GMP on record
• Lupin LimitedIndia1 active DMF GMP on record
• APITORIA PHARMA PRIVATE LTDIndia1 active DMF GMP on record
• Torrent PharmaceuticalsIndia1 active DMF GMP on record
• CF PHARMA LTD
• Sun Pharmaceutical Industries LimitedIndia GMP on record
• CAMBREX PROFARMACO MILANO SRLItaly GMP on record

Showing 25 of 31 suppliers — see the full list in the app.

EU CEP holders (16)

Companies holding a valid EU Certificate of Suitability (CEP) for Lamotrigine, from the EDQM certification database. A CEP holder is a documented EU-market source of the substance — not necessarily the manufacturer — and these are not yet profiled in our directory.

Patent & exclusivity (US)

Per the FDA Orange Book (162 approved US products), the latest listed US patent on Lamotrigine expires 29 May 2040. Generic API sourcing typically opens up once these lapse.

Therapeutic areas